Jenkem Technology Announces Up to RMB 315 Million Investment in Bohai Meiwan Health Park Project
Jenkem
Developer and Manufacturer of Medical-Grade Polyethylene Glycol (PEG) Derivatives
On June 30, 2026, Jenkem (688356.SH) announced that its wholly-owned subsidiary, Tianjin Jenkem Technology Co., Ltd., plans to invest no more than RMB 315 million in the construction of the "Bohai Meiwang Jenkem Health Park Project."
It is reported that,The planned construction area of the project is approximately31,300 square meters, estimatedConstruction Commences on August 18, 2026Construction period: 24 months; planned construction includes research and production facilities, a comprehensive building, and a health industry incubator, aimed at expanding the production line for medical device products, R&D laboratories, and health industry incubation capabilities. Jenkem Technology asAmong the few domestic and international companies capable of industrial-scale production of high-purity, low-dispersity medical-grade polyethylene glycol (PEG) and its active derivativesone of the companies, primarily engaged in the research and development, production, and sales of medical-grade polyethylene glycol (PEG) and its active derivatives. Meanwhile, based on itsProprietary Polyethylene Glycol Synthesis and PEGylation Technologies, provides downstream customers with innovative technical services for polyethylene glycol (PEG) applications in the pharmaceutical industry, and independentlyDeveloping Innovative PEGylated Drugs and Class III Medical Devices。
About Jenkem
Jenkem Innovation Research Institute, a subsidiary of Jenkem Technology, was established inIn 2019, the Research Institute comprised eight departments: the Analytical Method Development Department, the Synthetic Method Development Department, the New Product Development Department, the Biopharmaceutical Development Department, the Formulation Department, the Clinical Medicine and Pharmacology Department, the Medical Aesthetics Device Department, and the Regulatory Affairs Department.
On April 23, 2025, the "Cross-linked Sodium Hyaluronate Gel for Injection," independently developed by Tianjin Jenkem Technology, a wholly-owned subsidiary of Jenkem Technology, was officially approved, with registration certificate number: National Medical Device Registration No. 20253130825.It is reported that the productIt is the first domestically developed PEG-crosslinked sodium hyaluronate gel with independent intellectual property rights, primarily indicated for injection into the mid-to-deep dermis of the nasolabial fold area to correct moderate to severe nasolabial fold wrinkles.
On May 28, 2025, the registration application for "Sodium Hyaluronate Composite Solution for Injection," independently developed by Tianjin Jenkem Technology, a wholly-owned subsidiary of Jenkem Technology, was accepted by the National Medical Products Administration.。It is reported that the sodium hyaluronate composite solution for injection is a Class III passive implantable medical device independently developed based on polyethylene glycol modification technology, with proposed indications for improving skin dryness and dull complexion in adults.
On August 16, 2025, the inaugural new product launch event for SILKROSE® was grandly held in Beijing by Jenkem.It is reported that,Silk Rose asChina's First PEG-Crosslinked Sodium Hyaluronate Gel with Independent Intellectual Property RightsUse novel PEG derivatives as cross-linking agents to replace traditional cross-linkers such as BDDE and DVS.
On June 17, 2026, two wholly-owned subsidiaries of Jenkem Technology in Tianjin and Liaoning obtainedThe ISO 20400 Sustainable Procurement Performance Assessment Statement issued by SGS, making it the first enterprise in China's medical and pharmaceutical polyethylene glycol (PEG) and its derivatives field to receive this statement from SGS.
